Buffett-Style Value Investment Analysis: Tempus AI, Inc. (TEM)

---

1️⃣ Circle of Competence Analysis

1.1 Is the Company's Business Easy to Understand?

Business Model

Tempus positions itself as an AI-enabled precision medicine company. It builds a multimodal healthcare data platform and monetizes it across three segments:

1. Genomics (Diagnostics)

   • NGS (Next Generation Sequencing)
   • Molecular diagnostics
   • Oncology testing
   • Hereditary testing
   • Connected to patient EHR data

2. Data & Services

   • Licensing de-identified clinical + molecular data to pharma
   • Clinical trial matching
   • Insights (data licensing analytics platform)

3. AI Applications

   • Algorithmic diagnostics
   • AI-enabled clinical decision tools
   • Software-as-a-medical-device initiatives

(Source: 10-K Business section )

Customers

• Hospitals and physicians (Diagnostics)
• Pharmaceutical and biotech companies (Data licensing)
• Healthcare systems (AI applications)

Revenue Composition (9M 2025)

• Genomics: $688.5M
• Data & Services: $216.1M
• Total: $904.6M

Preliminary FY2025 revenue: ~$1.27B (+83% YoY)

Revenue Nature

• Diagnostics = transaction-based
• Data licensing = recurring multi-year contracts
• AI applications = emerging

Revenue is transparent but still growth-stage and not yet profitable.

📌 Industry Classification Healthcare + AI + Diagnostics + Data SaaS Understandable structurally, but technically complex.

---

1.2 Is the Business Logic Clear for the Next 10 Years?

Industry Stage

• Precision oncology still early-stage.
• AI in healthcare accelerating.
• Diagnostics increasingly data-driven.

Growth Indicators

• FY2025 revenue growth ~83% YoY
• Diagnostics revenue growth ~111% YoY
• Data revenue growth ~31% YoY
• Net revenue retention ~126%
• Total Contract Value > $1.1B

Demand is clearly growing.

Predictability

• Diagnostics = semi-predictable volume growth
• Data licensing = contract-driven, higher visibility
• AI applications = speculative upside

📌 Conclusion (Circle of Competence) Business model understandable. Technology complexity high but strategic logic clear. ✔ Within Circle (for experienced healthcare investors).

---

2️⃣ Durable Competitive Advantage (Moat)

2.1 Brand

Tempus has strong brand in precision oncology. Major pharma customers (Pfizer, Merck, AstraZeneca, etc.)

But brand not yet pricing-power dominant like Roche.

Moat strength: Medium (brand credibility, not dominance).

---

2.2 Cost Advantage

High fixed cost platform:

• Data pipelines (~700 integrations)
• Labs across US
• AI model training

Scale improves margins.

Currently not profitable → cost advantage still emerging.

---

2.3 Switching Costs

Strong in:

• Data licensing (embedded in pharma workflows)
• Integrated datasets
• Long-term contracts

Net revenue retention 126% Indicates expansion within accounts.

Switching cost: Medium to High

---

2.4 Network Effect

Yes — data flywheel:

More tests → more data → smarter AI → more adoption.

Described in 10-K platform model

True data network effect likely the strongest moat element.

---

2.5 Scale Advantage

Diagnostics scale improving gross leverage.

However, still operating losses:

• 9M 2025 operating loss: $(191.5)M

Scale advantage not yet translated into profits.

---

📌 Overall Competitive Advantage Judgment: Moat = Medium (Data-driven moat, not yet fully proven economically)

---

3️⃣ Management

3.1 Integrity

No accounting scandals noted. Standard disclosures in 10-K

No red flags observed.

---

3.2 Execution

Revenue acceleration strong:

• 2024 → 2025 explosive growth
• Strong pharma contract expansion

However:

• Persistent net losses
• High operating burn

9M 2025 Net Loss: $(190.9)M

Execution strong on growth, weak on profitability discipline.

---

3.3 Alignment

Significant founder involvement (Eric Lefkofsky). Equity-based compensation high (seen in cash flow adjustments)

Some dilution risk due to growth capital raises.

---

📌 Overall Management Rating: B+ (Visionary, growth-focused, not yet capital-efficient)

---

4️⃣ Financials

4.1 Profitability

9M 2025:

• Revenue: $904.6M
• Operating Loss: $(191.5)M
• Net Loss: $(190.9)M

Net margin still deeply negative.

---

4.2 Returns

Negative ROE due to accumulated deficit:

• Accumulated deficit: $(2.34)B

ROIC currently negative.

---

4.3 Free Cash Flow

Operating cash flow (9M 2025): $(181.3)M

Still cash-consuming.

---

4.4 Capital Structure

Sept 30, 2025:

• Cash: $655.9M
• Convertible senior notes: $726.9M
• Total liabilities: $1.77B

Leverage increasing.

Balance sheet adequate for now, but debt rising.

---

4.5 Shareholder Returns

No dividend. No buybacks. Growth reinvestment phase.

---

📌 Overall Financial Assessment: High growth, high burn, leverage increasing. Financial profile = Speculative Growth Stage

---

5️⃣ Intrinsic Value

(The following content is exclusive to subscribers.)